B+
Bull case
20%
Probability
Target price
$1.55
+53.5% vs current
RKDA
Arcadia BiosciencesBNasdaq / Food Beverage & Tobacco
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.80
-20.8% vs current
B-
Bear case
35%
Probability
Target price
$0.30
-70.3% vs current
AI sentiment snapshot
Latest data as of 2026-05-22
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+25.1
Score
AI commentary
Primary-source tone is mixed but still cautious. The quarter showed a real operating improvement in Zola volumes and very low SG&A, yet management also explicitly said the company will need additional funding soon. No reliable post-print analyst revision signal, consensus estimate set, sufficient social-sentiment coverage, or options/short-interest signal was present in the packet, so conviction stays low and balance-sheet risk remains the dominant issue.
RankAlpha Sentiment Codex - 2026-05-22
Open full AI memoEvidence flagged
Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.
Impact
tentative
Confidence
-
AI events
2026-05-14catalystQ1 2026 print showed better Zola volumes but continued bottom-line pressureHigh impact
The May 14 release showed Zola coconut water unit volumes up 18% year over year and SG&A at the lowest level in Arcadia's history, but total revenues still fell 8% to $1.1 million and net loss attributable to common stockholders widened to $4.4 million. The print is supportive on operating discipline but still flags a fragile base [#8-K-2026-05-14].
2026-09-30eventFall 2026 new-product rollout could improve shelf presenceHigh impact
Management said it expects a new product to reach many of its largest customers in the fall, which could help offset the still-small revenue base if execution and distribution are solid. This is a real operating catalyst, but coverage is thin and the impact depends on customer adoption [#8-K-2026-05-14].
2026-10-31catalystCapital raise or asset monetization remains the key survivability leverHigh impact
The company says it will require additional funding in the near future, while the 10-K flagged that existing cash was not sufficient for the next 12 months. A credible financing, asset sale, or other liquidity bridge could materially reduce distress risk, but a dilutive outcome would likely pressure the stock [#10-K-2026-03-26].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-22 • Updated nightlySource: Internal modelMethodology